199 related articles for article (PubMed ID: 19012295)
1. Photocontrollable peptide-based switches target the anti-apoptotic protein Bcl-xL.
Kneissl S; Loveridge EJ; Williams C; Crump MP; Allemann RK
Chembiochem; 2008 Dec; 9(18):3046-54. PubMed ID: 19012295
[TBL] [Abstract][Full Text] [Related]
2. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of Bak derived peptides: affinity and specificity modulations by amino acid replacement.
Frey V; Viaud J; Subra G; Cauquil N; Guichou JF; Casara P; Grassy G; Chavanieu A
Eur J Med Chem; 2008 May; 43(5):966-72. PubMed ID: 17692431
[TBL] [Abstract][Full Text] [Related]
4. Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL.
Yin H; Lee GI; Sedey KA; Kutzki O; Park HS; Orner BP; Ernst JT; Wang HG; Sebti SM; Hamilton AD
J Am Chem Soc; 2005 Jul; 127(29):10191-6. PubMed ID: 16028929
[TBL] [Abstract][Full Text] [Related]
5. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies.
Petros AM; Nettesheim DG; Wang Y; Olejniczak ET; Meadows RP; Mack J; Swift K; Matayoshi ED; Zhang H; Thompson CB; Fesik SW
Protein Sci; 2000 Dec; 9(12):2528-34. PubMed ID: 11206074
[TBL] [Abstract][Full Text] [Related]
6. Structure and function of benzoylurea-derived alpha-helix mimetics targeting the Bcl-x(L)/Bak binding interface.
Rodriguez JM; Ross NT; Katt WP; Dhar D; Lee GI; Hamilton AD
ChemMedChem; 2009 Apr; 4(4):649-56. PubMed ID: 19330783
[TBL] [Abstract][Full Text] [Related]
7. A conserved hydrophobic core at Bcl-xL mediates its structural stability and binding affinity with BH3-domain peptide of pro-apoptotic protein.
Feng Y; Zhang L; Hu T; Shen X; Ding J; Chen K; Jiang H; Liu D
Arch Biochem Biophys; 2009 Apr; 484(1):46-54. PubMed ID: 19161970
[TBL] [Abstract][Full Text] [Related]
8. Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction.
Yin H; Lee GI; Sedey KA; Rodriguez JM; Wang HG; Sebti SM; Hamilton AD
J Am Chem Soc; 2005 Apr; 127(15):5463-8. PubMed ID: 15826183
[TBL] [Abstract][Full Text] [Related]
9. Oligomerization of BH4-truncated Bcl-x(L) in solution.
Wang Y; Cao R; Liu D; Chervin A; Yuan J; An J; Huang Z
Biochem Biophys Res Commun; 2007 Oct; 361(4):1006-11. PubMed ID: 17692289
[TBL] [Abstract][Full Text] [Related]
10. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.
Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK
J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577
[TBL] [Abstract][Full Text] [Related]
11. Photocontrol of DNA binding specificity of a miniature engrailed homeodomain.
Guerrero L; Smart OS; Woolley GA; Allemann RK
J Am Chem Soc; 2005 Nov; 127(44):15624-9. PubMed ID: 16262429
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.
Petros AM; Dinges J; Augeri DJ; Baumeister SA; Betebenner DA; Bures MG; Elmore SW; Hajduk PJ; Joseph MK; Landis SK; Nettesheim DG; Rosenberg SH; Shen W; Thomas S; Wang X; Zanze I; Zhang H; Fesik SW
J Med Chem; 2006 Jan; 49(2):656-63. PubMed ID: 16420051
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship studies of phenanthridine-based Bcl-XL inhibitors.
Bernardo PH; Wan KF; Sivaraman T; Xu J; Moore FK; Hung AW; Mok HY; Yu VC; Chai CL
J Med Chem; 2008 Nov; 51(21):6699-710. PubMed ID: 18925736
[TBL] [Abstract][Full Text] [Related]
14. Heat-induced dimerization of BCL-xL through alpha-helix swapping.
Denisov AY; Sprules T; Fraser J; Kozlov G; Gehring K
Biochemistry; 2007 Jan; 46(3):734-40. PubMed ID: 17223694
[TBL] [Abstract][Full Text] [Related]
15. Structural model of the BCL-w-BID peptide complex and its interactions with phospholipid micelles.
Denisov AY; Chen G; Sprules T; Moldoveanu T; Beauparlant P; Gehring K
Biochemistry; 2006 Feb; 45(7):2250-6. PubMed ID: 16475813
[TBL] [Abstract][Full Text] [Related]
16. mRNA display selection of a high-affinity, Bcl-X(L)-specific binding peptide.
Matsumura N; Tsuji T; Sumida T; Kokubo M; Onimaru M; Doi N; Takashima H; Miyamoto-Sato E; Yanagawa H
FASEB J; 2010 Jul; 24(7):2201-10. PubMed ID: 20181936
[TBL] [Abstract][Full Text] [Related]
17. High-yield expression and purification of soluble forms of the anti-apoptotic Bcl-x(L) and Bcl-2 as TolAIII-fusion proteins.
Nedelkina S; Gokce I; Ridley H; Weckerle C; Magnin T; Vallette F; Pattus F; Lakey JH; Bechinger B
Protein Expr Purif; 2008 Aug; 60(2):214-20. PubMed ID: 18522870
[TBL] [Abstract][Full Text] [Related]
18. The N-terminal domain of tumor suppressor p53 is involved in the molecular interaction with the anti-apoptotic protein Bcl-Xl.
Xu H; Tai J; Ye H; Kang CB; Yoon HS
Biochem Biophys Res Commun; 2006 Mar; 341(4):938-44. PubMed ID: 16455050
[TBL] [Abstract][Full Text] [Related]
19. Paralog-selective ligands for bcl-2 proteins.
Gemperli AC; Rutledge SE; Maranda A; Schepartz A
J Am Chem Soc; 2005 Feb; 127(6):1596-7. PubMed ID: 15700967
[TBL] [Abstract][Full Text] [Related]
20. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
Shin JS; Ha JH; Chi SW
Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
